Oropharyngeal Cancer: Navigating Trials and Innovations in Patient Matching

The diagnostic odyssey

Oropharyngeal cancer, a malignancy that affects the back of the throat, including the base of the tongue and the tonsils, has become increasingly prevalent, particularly among younger populations. This cancer type is often associated with the human papillomavirus (HPV), which complicates both diagnosis and treatment strategies. The journey to diagnosis can be lengthy, as symptoms such as sore throat, difficulty swallowing, and unexplained weight loss may be mistaken for less severe conditions. The complexity of oropharyngeal cancer further complicates the identification of eligible patients for clinical trials, as many individuals may not be aware of their cancer status until it reaches an advanced stage.

Patients often undergo a series of diagnostic tests, which can include imaging studies and biopsies, before receiving a definitive diagnosis. This diagnostic odyssey leads to delays in treatment and can impact overall outcomes. The challenge of finding eligible patients for clinical trials is exacerbated by these delays, as only a fraction of diagnosed individuals meet the stringent criteria set by trial sponsors.

The trial landscape right now

Currently, our live trial registry indicates that there are 17 clinical trials actively recruiting participants for oropharyngeal cancer across 52 sites in 9 countries. The trials are diverse in their phases, with 7 trials categorized as N/A, 6 in Phase II, 3 in Phase I, and 1 in Phase III. Leading sponsors include prominent institutions such as Washington University School of Medicine and Mayo Clinic, each sponsoring two trials.

Geographically, the United States leads with 14 trials, followed by China with 11, and France with 8. Notable trials include NCT04852328, which explores three schedules of CUE-101 administered before surgery or definitive chemoradiation therapy for HPV16-positive patients. Another significant study, NCT05268614, investigates risk-adapted de-intensification of radio-chemotherapy for oropharyngeal squamous cell carcinoma. These trials represent a commitment to advancing treatment options and improving outcomes for patients battling this challenging disease.

How we detect the match

The integration of HL7 and FHIR standards, combined with artificial intelligence, presents a groundbreaking approach to patient matching for clinical trials. By leveraging existing clinical data, healthcare institutions can efficiently identify eligible patients without the need for manual chart review.

For instance, using specific FHIR resources like Condition, Observation, MedicationRequest, and DiagnosticReport, healthcare systems can extract relevant information about a patient’s condition, treatment history, and laboratory results. Signals from lab results, genetic markers, and ICD-10 codes can be utilized to create computable phenotypes that define eligibility criteria for clinical trials. This AI-driven approach not only accelerates patient identification but also enhances the accuracy of matching patients to the right trials, ensuring that those who could benefit from innovative therapies are not overlooked.

Beyond the trial: better care

The advantages of integrating HL7/FHIR with AI extend beyond trial enrollment. By streamlining the diagnostic process, this technology can significantly shorten the time it takes for patients to receive a diagnosis and initiate treatment. Enhanced coordination of care leads to better monitoring of patient progress and outcomes, irrespective of whether a patient enrolls in a trial.

Real-time data integration allows for timely adjustments in treatment plans based on the most current clinical evidence and patient responses. This approach fosters a more patient-centered healthcare environment, where care is tailored to individual needs and preferences, ultimately improving the overall patient experience and outcomes in oropharyngeal cancer care.

The takeaway

Oropharyngeal cancer poses significant challenges in diagnosis and treatment, complicating the search for eligible trial participants. However, the current landscape of clinical trials and innovative patient matching strategies using HL7 and FHIR technologies offer promising pathways to enhance patient care and treatment outcomes. By improving the efficiency of patient identification and care coordination, we can ensure that more individuals gain access to potentially life-saving therapies and a better quality of care.